Liothyronine
Active ingredient
Sold as CYTOMEL
- Drug class
- -
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 35
Overview
Liothyronine is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 24 | June 2, 2026 |
| CA Canada | Health Canada | 8 | January 20, 2026 |
| US United States | FDA | 3 | May 3, 2026 |
GBUnited Kingdom· MHRA
24 products
Uses
Liothyronine is indicated in adults and children for the treatment of coma of myxedema, the management of severe chronic thyroid deficiency and hypothyroid states occurring in the treatment of thyrotoxicosis. Liothyronine sodium can be used also as an adjunct to carbimazole to prevent subclinical hypothyroidism developing during carbimazole treatment of thyrotoxicosis.
Liothyronine sodium may be preferred for treating severe and acute hypothyroid states because of its rapid and more potent effect, but thyroxine sodium is normally the drug of choice for routine replacement therapy.
How to take
CACanada· Health Canada
8 products
Uses
AND CLINICAL USES
Cytomel® is indicated in conditions of inadequate endogenous thyroid production. These: include: a.
HYPOTHYROIDISM:
As replacement or supplemental therapy in patients with hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis b.
SIMPLE (non-toxic) GOITER:
Cytomel® may be tried therapeutically in an attempt to reduce the size of such a goiter, the rationale being that suppression of pituitary thyroid stimulating hormone (TSH) removes at least one of the growth-promoting factors. Cytomel® may be used in the T3 suppression test to differentiate suspected hyperthyroidism from euthyroidism.
(See special instructions under ADMINISTRATION AND DOSAGE), Cytomel® can be used in patients allergic to dessicated thyroid or thyroid extract derived from pork or beef.
USUnited States· FDA
3 products
Uses
3 ) Limitations of Use : - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. ( 1 ) - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
1 Hypothyroidism Liothyronine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. 2 Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Liothyronine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer .
3 Thyroid Suppression Test Liothyronine sodium tablets are indicated as a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. 4) ] . Liothyronine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
Drug interactions
Known interactions involving Liothyronine. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 284. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL001421256 · revised May 15, 2026
- [2]Health Canada (DPD) · 01919458 · revised March 22, 2025
- [3]FDA DailyMed · 0b0f2db9-642d-d8… · revised March 15, 2024 [PDF]
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.